“…Carbapenemase (e.g., IMP, VIM, KPC, and NDM)-producing E. cloacae isolates have been reported (2,3,9,12). However, to the best of our knowledge, the risk factors, epidemiology, and clinical effects pertaining to IMP-type MBL-producing E. cloacae have not been systematically evaluated, in contrast to other carbapenemase-producing pathogens, such as KPC producers (13,14).…”